Overview of the lenograstim pharmacoeconomics programme

Area of Science:

• Oncology
• Pharmacoeconomics
• Hematology

Background:

• Lenograstim is a recombinant granulocyte colony-stimulating factor (rG-CSF).
• It serves as an adjunctive therapy in cancer chemotherapy.
• Lenograstim addresses chemotherapy-induced neutropenia and facilitates dose intensification.

Purpose of the Study:

• To establish a lenograstim pharmacoeconomics program.
• To conduct prospective economic evaluations of lenograstim.
• To gather economic data for a new drug entity.

Main Methods:

• Lenograstim's efficacy was assessed in Phase III randomized clinical trials.
• Pharmacoeconomic evaluations were integrated into these trials.
• Studies were conducted by international health-economics teams in Germany, Italy, France, and the UK.

Main Results:

• Lenograstim demonstrated efficacy in correcting chemotherapy-induced neutropenia.
• It proved useful in managing associated complications in inflammatory breast cancer and non-Hodgkin's lymphoma.
• Lenograstim facilitated dose intensification in small cell lung cancer treatment.

Conclusions:

• Lenograstim is an effective adjunctive agent in cancer chemotherapy.
• Pharmacoeconomic data were prospectively collected alongside clinical efficacy data.
• The studies support the economic evaluation of lenograstim in specific cancer types.